NAGE — Niagen Bioscience Inc
NASDAQ · Consumer Products · Consumer Products
- Latest Close
- $4.74
- 30-Day Move
- -28.5%
- Market Cap
- $351M
- Shares Outstanding
- 80,080,000
- P/E Ratio
- 20.18
- P/B Ratio
- 6.63
Analyst consensus: Buy · 11 analysts
Niagen Bioscience Inc
A read-only Alphactor snapshot for Niagen Bioscience Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of 2026-04-21
Topline snapshot
Latest Close
$4.74
30-Day Move
-28.5%
Market Cap
$351M
Shares Outstanding
80,080,000
P/E Ratio
20.18
P/B Ratio
6.63
$4.74
-28.5%last 90 delayed daily bars
90D High
$7.05
90D Low
$4.16
Avg Volume
1,055,097
Gross margin is running at 64.3%, which gives a quick read on operating quality before you open the full model.
Net margin is 13.4%, useful for comparing NAGE against peers in Consumer Products.
NAGE is down 28.5% over the last 30 trading days shown on this page.
Latest operating income is $2M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$6.96
Rule of 40
40.2%
Latest Close
$4.74
30-Day Move
-28.5%
Market Cap
$351M
Shares Outstanding
80,080,000
P/E Ratio
20.18
P/B Ratio
6.63
ROE
22.7%
ROA
16.3%
Gross Margin
64.3%
Operating Margin
12.6%
Net Margin
13.4%
Debt / Equity
0
Current Ratio
4.86
Latest Revenue
$34M
Revenue
$34M
Gross Profit
$22M
Operating Income
$2M
Net Income
$4M
Gross Margin
6428.0%
Net Margin
1343.0%
Current Ratio
4.86
Debt / Equity
0.00
Fair Value
$6.96
Upside / Downside
+46.9%
Signal
Undervalued
Implied Growth
10.4%
DCF
$5.08
EV/Rev
$8.85
Growth Assumption
21.6%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
$13M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Altman Z
7.41
Safe
Piotroski
6
Moderate (4-6)
Cash Conversion
0.78x
Rule of 40
40.2%
Strong
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $72M | $-19M | $-17M | $-15M |
| 2023-12-31 | $84M | $-6M | $-5M | $7M |
| 2024-12-31 | $100M | $8M | $9M | $12M |
| 2025-12-31 | $129M | $14M | $17M | $13M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
BlackRock
Filed 2024-08-13
$9M
--
Renaissance Technologies
Filed 2025-08-13
$7M
-6.4%
Citadel Advisors
Filed 2026-02-17
$2M
--
4.27
Consensus
Buy—
—
—
11
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.